Regeneron Pharmaceuticals, Inc is a biotechnology company founded in 1988 and headquartered in the United States. It employs more than 15,000 people, including over 1,400 with MD and/or PhD qualifications, and operates across a global network. The company was founded and continues to be led by physician-scientists, with research and development at the centre of its work: almost all of its approved treatments and pipeline candidates originated in its own laboratories.
The company's scientific infrastructure includes several proprietary platforms. VelociSuite® is its antibody discovery technology, capable of producing optimised fully human antibodies as well as new classes of bispecific antibodies. The Regeneron Genetics Center® (RGC) generates data-powered insights from large-scale human genetics research. Regeneron also develops genetic medicine platforms, though specific product details have not been disclosed publicly at this time.
Regeneron's pipeline spans a broad range of therapeutic areas, including oncology, ophthalmology, allergic and inflammatory conditions, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases, and rare diseases. The company covers the full drug lifecycle - from discovery and development through to commercialisation - across multiple geographies.
